As the Founder and CEO of TBioScan Diagnostics, I am driven by a passion for discovery and a commitment to advancing patient care. Recognizing critical gaps in the field of personal injury and traumatic brain injury (TBI) diagnostics, I channeled my expertise into developing and validating a groundbreaking panel of protein and genetic biomarkers. This innovative panel is designed to accurately assess TBI and monitor its progression over time.Through rigorous research and innovation, I successfully translated these biomarkers from the lab to clinical practice, revolutionizing how TBI is diagnosed and managed. By setting new standards in precision and effectiveness, my work aims to empower healthcare professionals with better tools for patient care, improving outcomes for those affected by TBI.

BioCentra LLC is engaged in advancing research and development in biomedical sciences and biotechnology through education, technology innovation, new product development, customized research services, strategic consulting, and project management, by collaborating with industry and academia, both nationally and internationally.Services:◘ Consulting and contract negotiations for biopharmaceutical and biotechnology companies in technology transfer, manufacturing, product distribution, and marketing.◘ Development of protocols, scientific procedures, market content, pitch decks, scientific proposal, and business plans for clients in healthcare and biotechnology. ◘ Preclinical development of diagnostic products and biotherapeutics ◘ Negotiation and management of international technology transfer and drug distribution deals.Expertise:◘ Broad experience in biomedical research and biotechnology methods and protocols◘ Extensive networking experience with clinical, scientific and industrial decision makers and KOLs◘ Skilled in the art of intellectual property evaluation, protection, and patent filing◘ Comprehensive knowledge of legal and regulatory issues in technology transfer, product commercialization and business development in developed and emerging markets◘ Hands-on experience in developing novel technology platforms in peptide-based vaccines, oncology therapeutics and molecular diagnostics.◘ Design and development of Novel Technology platforms for Antibody and Peptide-based Drugs◘ Computational and Statistical Analysis of Scientific, Technical and Market Data◘ Wide-ranging experience in forging national and international collaborations◘ Extensive Networking with clinical, scientific and industrial decision makers KOLs◘ Experience of grant (SBIR/STTR) writing and collaborative research with industry and academia◘ Experience in creating compelling content and social media campaigns for branding and fundraising.

Developed a lipid-based nanotechnology system for the delivery of several protein molecules for use as drug candidates. The technology development process required formulating a GLP-compliant method and transfer of entire technology to a GMP facility for large scale production.

• Established a scientific team for extensive characterization of product. Managed the work that leads to the claim of Biosimilarity through detailed product characterization like Primary structure analysis (protein sequencing, S-S linkage, peptide mass fingerprinting using LC-MS, detail analysis of chemical modifications and their effect, evaluating thermal stability of the product, biophysical characterization (CD spectroscopy, fluorescence spectroscopy), Glycan analysis (characterization of the oligosaccharides, analysis of the linkages in monosaccharides, site of glycosylation using MS) and analysis of other product heterogeneity (charge variants).• Integrated the product development from animal toxicity campaign to clinical campaign. Played strategic role in streamlining the policies for IRS establishment strategy, specification setting strategy.

PGx (Pharmacogenomics) Global Foundation is a nonprofit organization (EST. 2022) with a mission to educate the individuals and the healthcare providers about the benefits of PGx testing. PGx Global also offers low-cost PGx testing to individuals with co-morbid conditions associated with polypharmacy in underserved communities in and around Houston, Texas. Data generated from these tests will be used by their healthcare providers to offer better quality of care and targeted therapeutics thereby avoiding adverse drug reactions and death. Genomic insights created from the accumulated data will help advance targeted new therapies in the future.

BioCentra Diagnostics LLC, established in 2016, is a Texas-based CLIA accredited molecular and genomic diagnostics laboratory with a focus on applying GWAS in understanding infectious and metabolic disease dynamics in diverse populations by utilizing modern advances in genome sequencing and artificial intelligence. Our goal is to forge collaborations with national and international organizations with interest in acquiring such data in understanding meaningful association in developing a pathway for personalized clinical care.

Established a network of CLIA and CAP certified reference laboratories in the State of Texas that required working collaboratively on fulfilling a broad test menu consisting of cytogenetic tests (FISH, FACS, IHC and, molecular genetics tests involving single genes, and multiple gene panels); molecular microbiology assays; WES using next-gen sequencing, involving new library construction for new gene mutations using platforms from Roche, Abbott, Biofire, Illumina, molecular targets for infectious disease, complex scientific projects, delivering solutions and establishing a strong client and interpersonal relationship with all stakeholders including clients.

Incorporated as a nonprofit organization in 2018, American Biotechnology Institute (ABTI) serves as a resource and training platform for young scientists, innovators & entrepreneurs. ABTI engages engages and leads students in workshops and training events. Located in the greater Austin area, ABTI is on a mission to train and nurture a generation of young scientists (promising low-income high school and college students), innovators and social entrepreneurs from the State of Texas leading to innovate solutions concerning food security, environment, and medicine. ABTI has active collaborations with the National Center for Therapeutics Manufacturing (NCTM) and Texas Experimental Engineering Station (TEES) at Texas A&M University for workforce development training in Biopharmaceutical Manufacturing and Technology.Activities at ABTI include the following:◘ Provided training to high school and college students in scientific innovation and entrepreneurship.◘ Wrote training materials, protocols, scientific procedures, safety guidelines, website content, pitch deck, innovation labs proposal and business plans.◘ Collaborated with principals and top management from Harmony Public Schools in Texas, academicians from UT Austin and Rice, investigators from the community college, physicians from local healthcare organizations, and entrepreneurs from healthcare and life sciences organizations in Austin and across the nation to muster support for the organizational mission.◘ Conducted first summer training camp in June 2018 in collaboration with Rice University and Harmony Public Schools in Austin, Texas.◘ Lectured in schools and colleges and spoke at events in presence of learned audiences.◘ Collaborated with student outreach organizations and local incubators◘ Presented proposals for seeking support from Dell Medical School and the UT, Austin.

TopBlood establish in 2019, is a Texas-based CLIA accredited molecular diagnostics laboratory with a focus on providing access to standard, preventive, molecular infectious disease, genomic and Pharmacogenomics testing services by simplifying access to cutting-edge human diagnostic technology and creating a seamless ordering experience without a need to travel long distances for lab testing or the requirement of a doctor’s order or to have a medical insurance. We have partnered nationally with more than 2500 labs to make the standard lab testing ubiquitously accessible and reasonably affordable.TopBlood not only helps the local community with affordable lab testing but also caters to the physician offices by providing high complexity molecular testing including cancer and infectious disease.

Designed and developed specialized peptide molecules as standards with quantitative applications in prenatal diagnostics development.

Helped Avalon Pharma acquire technology transfer and drug distribution contracts worth $100M.

Consulted MPS for adopting biosimilar and nanotechnology for new drug development. Helped them acquire collaborations and commercial contracts with the drug developers and technology providers.

BCMI was incorporated in New Jersey and Texas to seek regulatory approval and commercialize a molecular diagnostic assay kit for HCV viral load. We raised two rounds of investment, acquired IP, validated the product and conducted clinical trials with the Centers for Disease Control, Atlanta and other research organizations.

Consulted and assisted Macter International in seeking access to bisimilar technology and biopharmaceutical products; biotechnology infrastructure and out-licensing opportunities from pharmaceutical companies and technology providers in the U.S. and E.U. The consulting engagement encompassed help with regulatory, formulation, and commercialization strategies in Pakistan.

◘ Consulted ARABIO in developing blueprint for the implementation of Oncology Biosimilar product manufacturing in KSA. ◘ Interacted with different MOH officials in Pakistan, Bangladesh and emerging markets (MENA countries including GCC countries, South East Asian, and ASEAN countries) for marketing authorization of collaborator products.◘ Networked with Saudi FDA officials, clinical investigators and KOLs in Oncology from leading hospitals and research centers (like NGHA, KAIMRC, KFSHRC and KFMC) in KSA, to mobilize the change in opinion in support of adopting new technology in medicine, performing clinical trials and engaging in post-market surveillance and bioequivalencestudies of newly approved biopharmaceuticals and other Biosimilar molecules.◘ Managed to mobilize opinion, drive the interest of thought leaders and decision-makers in developing a lateral thinking attitude in order to solve complex problems posed by the varied and non-harmonized global regulatory systems that has its direct impact on the pharmaceutical, biopharmaceutical and the medical device industry leading to impediments in their clinical development, approval process, marketability, access to patients and finally to the loss of revenues to the industry.

Ebaada Healthcare Solutions (EHCS), LLC was primarily incorporated to support physician offices adopt Electronic Health Records platform to manage the patient records and manage healthcare payment processes including overseeing fraud and abuse in medical claims. Business development at EHCS involved regular liaison with HCPs and their office managers.Visiting HCP offices (mostly in Texas metro cities) for software installation and interacting with HCPs about best solutions and practices developed by our organization. Onboarding process also involved credentialing of HCPs with Insurance companies and reference laboratories.In 2 years, EHCS grew from 11 practices in the first year to 28 practices in the second year.

My role at Alpha Diagnostics International, LLC involved developing a molecular biology service division for the company and helping scientists with the bioinformatic analysis of proteins and peptides, and the development of ELISA assays, and antibodies for use in in vitro research. These job responsibilities and activities resulted in boosting company revenues in custom peptide and antibody division by 40% in 2 years. Further responsibilities comprised of the following activities:◘ Managed projects, supervised people and established a molecular diagnostic division.◘ Developed a novel method to produce antibodies against peptides labeled with Nitric Oxide.◘ Developed ELISA assays for markers associated with Multiple Sclerosis◘ Provided technical support to researchers from industry and academia.◘ Helped more than 300 scientists all over the world in the computational analysis of proteins.◘ Devised a new computational method for identifying linear B-cell epitopes for therapeutic antibody and anti-peptide vaccine design.

As a postdoctoral research fellow, studied the role of FGF18 in limb development and organogenesis of the midbrain. This work involved the use of state of the art molecular, cell biology and bioinformatics techniques. Managed doctoral students and technicians; presented scientific data in the lab and in conferences. Interacted with faculty and other research staff. Reviewed manuscripts and wrote grant applications.

As Guest Scientist at the Institute for Human Genetics, National Research Center for Environment and Health, Neuherberg, Germany, successfully characterized adult retinal and neuronal stem cells and studied pathways induced by GDNF in retinal neuronal protection.- Characterization of Adult Retinal Stem Cells - Gene cloning and cell biology. - Devised a protocol to extract adult retinal stem cells from human eye.- Successfully characterized adult retinal and neuronal stem cells.- Cloned several genes used for studying pathways induced by GDNF, a neuronal growth factor.

The project work during my period at CDFD was solely dedicated to the cloning and characterization of genes for the silk worm genome project. Much of the work was focused on the characterization of silkworm alpha amylase gene using bacteriophage vectors to clone full length genomic clones and the screening of cDNA libraries for cDNA clones.

As a Senior Research Fellow at the Center for Biotechnology, Jawaharlal Nehru University, New Delhi, India, screened 60 hospitalized oral cancer patients for hotspot mutations in Tumor suppressor gene P53; devised a robust method for screening of p53 tumor suppressor gene in oral cancer biopsy samples; learned hardcore molecular biology techniques.